Financial Performance - For the nine months ended September 30, 2025, the company incurred net losses of $7.7 million compared to $17.1 million for the same period in 2024, reflecting a decrease of $9.4 million[83]. - The total operating expenses for the three months ended September 30, 2025, were $2.5 million, a decrease of $9.8 million from $12.3 million in the same period of 2024[88]. - General and administrative expenses decreased by $1.2 million for the nine months ended September 30, 2025, primarily due to a reduction in professional services[92]. - The company expects to continue incurring significant expenses and increasing operating losses over the next several years as it advances its clinical programs[83]. - The company reported a net cash outflow of $2.6 million in cash and cash equivalents for the nine months ended September 30, 2025, compared to an increase of $18.3 million in the same period of 2024[100]. - A settlement payment of $2.5 million to the Securities and Exchange Commission contributed to the cash outflow in operating activities for the nine months ended September 30, 2025[101]. Research and Development - Research and development expenses for the three months ended September 30, 2025, increased by $0.2 million primarily due to costs associated with the Phase II clinical trial of stenoparib[89]. - Research and development expenses for the nine months ended September 30, 2025, increased by over $0.7 million, mainly due to the launch and expansion of the Phase II clinical trial[90]. - The FDA granted Fast Track designation for stenoparib for the treatment of advanced ovarian cancer, which may expedite its development and review process[77]. - The company anticipates substantial expenses for the development and potential commercialization of its drug candidate, stenoparib, and may require additional funding in the future[98]. Cash and Financing Activities - The company had cash and cash equivalents of $16.9 million as of September 30, 2025, with an accumulated deficit of $126.8 million[95]. - Financing activities provided net cash of $10.9 million for the nine months ended September 30, 2025, including proceeds from the sale of common stock and prefunded warrants[103]. - The company believes its current cash balance is sufficient to fund operations for at least the next 12 months, but may need to seek additional capital[97]. - The company entered into a Securities Purchase Agreement to sell 1,562,500 shares at $1.60 per share, resulting in gross proceeds of approximately $2.5 million[79]. - The company sold 9,719,173 shares of common stock for net proceeds of $9.7 million during the nine months ended September 30, 2025[97]. - The company repurchased 2,600,763 common shares as part of a share repurchase program for $2.7 million during the nine months ended September 30, 2025[103]. - The company repurchased 145,061 shares for an aggregate cost of $140,038 during the three months ended September 30, 2025, with $2.3 million remaining under the share repurchase program[75]. Operational Insights - Operating activities resulted in a net cash outflow of $11.6 million for the nine months ended September 30, 2025, primarily due to a net loss of $7.9 million[101]. - The company has no off-balance sheet arrangements[106]. - There have been no significant changes to the company's accounting policies during the nine months ended September 30, 2025[108].

Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding 25 months in ongoing Phase 2 trialAdvanced DRP® platform through new licensing agreement TARPON SPRINGS, Fla., November 14, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial ...

Core Insights - The median Overall Survival (mOS) for patients with platinum-resistant and refractory ovarian cancer receiving stenoparib exceeds 25 months, marking a significant improvement over existing therapies [1][3][4] - The clinical trial data presented at the AACR conference indicates that stenoparib shows clinical benefit in both BRCA wild-type and BRCA mutant patients, highlighting its unique mechanism of action as a dual inhibitor [2][3][5] - Stenoparib demonstrates a favorable safety profile with less myelotoxicity compared to earlier-generation PARP inhibitors, addressing the need for effective treatments in heavily pre-treated ovarian cancer patients [4][5] Clinical Trial Data - The ongoing Phase 2 trial includes patients with advanced ovarian cancer who are platinum-resistant or refractory, with a Stenoparib-specific Drug Response Predictor (DRP) score above 50 [2][3] - Two patients have been on therapy for over 24 months, including one with a wild-type BRCA gene, which typically does not respond well to PARP inhibitors [2][3] - The current Kaplan-Meier estimate for mOS has not yet been reached, with a median follow-up time of nearly 22 months, indicating promising long-term outcomes [3][4] Drug Mechanism and Development - Stenoparib is a dual-targeted inhibitor of PARP1/2 and tankyrase 1/2, with potential applications across various cancer types due to its action on the WNT signaling pathway [6][8] - Allarity Therapeutics has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. [6][8] - The company is actively enrolling patients in a new Phase 2 trial protocol specifically for platinum-resistant or platinum-ineligible patients to expedite the drug's development towards FDA approval [3][6] Drug Response Predictor (DRP) - The DRP is utilized to select patients likely to benefit from stenoparib based on their cancer's gene expression signature, enhancing the therapeutic benefit rate [7] - The DRP platform has shown significant predictive ability for clinical outcomes across various cancer studies, supporting personalized treatment approaches [7]

Core Insights - Allarity Therapeutics, Inc. is a Phase 2 clinical-stage pharmaceutical company focused on developing stenoparib, a dual PARP and WNT pathway inhibitor, and its CEO has been invited to present at the Biomarkers & Precision Medicine 2025 conference in London [1][2] Company Overview - Allarity Therapeutics is dedicated to developing personalized cancer treatments, particularly stenoparib for advanced ovarian cancer patients, utilizing its Drug Response Predictor (DRP) technology [5] - The company has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. [3] Drug Information - Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2, showing potential therapeutic action against various cancers, including ovarian cancer [3] - The DRP companion diagnostic platform is designed to select patients likely to benefit from specific drugs based on gene expression signatures, enhancing therapeutic benefit rates [4] Conference Participation - CEO Thomas Jensen will present a talk titled "A Gene Expression Based Biomarker For Predicting Response To Treatment With Stenoparib" at the conference on October 1, 2025, and will be available for individual meetings to discuss business development opportunities [6][8]

Core Insights - Allarity Therapeutics has received Fast Track designation from the FDA for its investigational treatment stenoparib, aimed at patients with advanced ovarian cancer [1][2][3] Company Overview - Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments, particularly stenoparib, a dual PARP and WNT pathway inhibitor [6] - The company is headquartered in the U.S. and has a research facility in Denmark, committed to addressing significant unmet medical needs in cancer treatment [6] Drug Development - Stenoparib is an orally available small-molecule inhibitor targeting PARP1/2 and tankyrase 1/2, with potential applications in various cancer types, including ovarian cancer [4] - The FDA's Fast Track designation allows for more frequent interactions with the FDA and may lead to accelerated approval and priority review [2] - Allarity has initiated patient enrollment in a new Phase 2 clinical trial for stenoparib, focusing on advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer [3] Clinical Trial Insights - The ongoing Phase 2 trial builds on previous encouraging data, with some patients remaining on treatment for over 22 months [3] - The Drug Response Predictor (DRP) companion diagnostic is utilized to select patients likely to benefit from stenoparib based on their cancer's gene expression signature [5] Market Potential - The Fast Track designation highlights the significant unmet medical need for effective treatments in advanced ovarian cancer, indicating a promising market opportunity for stenoparib [2][3]

PART I—FINANCIAL INFORMATION [Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) Allarity Therapeutics' unaudited condensed consolidated financial statements detail financial position and performance as of June 30, 2025 [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheets as of June 30, 2025, show total assets of **$21.2 million** and total stockholders' equity of **$12.2 million** | Balance Sheet Highlights (in thousands) | June 30, 2025 (Unaudited) | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $17,801 | $19,533 | | Total current assets | $20,883 | $22,341 | | Total assets | $21,205 | $22,650 | | **Liabilities & Equity** | | | | Total current liabilities | $9,038 | $10,839 | | Total liabilities | $9,038 | $10,839 | | Total stockholders' equity | $12,167 | $11,811 | | Total liabilities and stockholders' equity | $21,205 | $22,650 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) The statements of operations show a net loss of **$2.3 million** for Q2 2025 and **$5.1 million** for H1 2025 | (in thousands) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $2,321 | $1,058 | $3,724 | $3,228 | | General and administrative | $1,812 | $2,313 | $3,445 | $4,383 | | Loss from operations | $(4,133) | $(3,371) | $(7,169) | $(7,611) | | Net loss | $(2,320) | $(1,629) | $(5,052) | $(5,472) | | Net loss per common share | $(0.15) | $(3.34) | $(0.38) | $(21.78) | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) The cash flow statements detail **$8.2 million** net cash used in operations and **$8.6 million** provided by financing for H1 2025 | (in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(8,167) | $(8,703) | | Net cash provided by financing activities | $8,578 | $27,689 | | Effect of exchange rate changes on cash | $(2,143) | $81 | | Cash and cash equivalents, end of period | $17,801 | $19,233 | - Financing activities in the first six months of 2025 included **$11.1 million** in net proceeds from ATM stock sales, offset by a **$2.6 million** common stock repurchase[24](index=24&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes provide critical details on accounting policies, liquidity, reverse stock splits, and the SEC investigation settlement - The company believes its existing cash of **$17.8 million** as of June 30, 2025, is sufficient to fund operations for at least the next 12 months, despite having an accumulated deficit of **$124.0 million** and negative cash flows from operations of **$8.2 million** for the period[28](index=28&type=chunk) - The company effected two reverse stock splits in 2024: a **1-for-20** split on April 9 and a **1-for-30** split on September 11. All share and per-share data have been retroactively adjusted[30](index=30&type=chunk) - On March 3, 2025, the board approved a **$5 million** share repurchase program. During the three months ended June 30, 2025, the company repurchased **2,455,702 shares** for approximately **$2.6 million**[52](index=52&type=chunk) - The company reached a final settlement with the SEC regarding a previously disclosed investigation and made a one-time civil penalty payment of **$2.5 million** on April 2, 2025[67](index=67&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=16&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial performance, liquidity, and operational developments, including R&D and G&A expense changes and cash sufficiency [Results of Operations](index=19&type=section&id=Results%20of%20Operations) Operating expenses decreased slightly for H1 2025, with R&D increasing by **$0.5 million** and G&A decreasing by **$0.9 million** | ($ in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | Increase/(Decrease) | | :--- | :--- | :--- | :--- | | Research and development | $3,724 | $3,228 | $496 | | General and administrative | $3,445 | $4,383 | $(938) | | Total operating expenses | $7,169 | $7,611 | $(442) | | Net loss | $(5,052) | $(5,472) | $420 | - The increase in R&D expenses for the six months ended June 30, 2025, was driven by costs related to the expansion of the Phase II clinical trial for stenoparib in Advanced Ovarian Cancer, including increases in regulatory costs, clinical site fees, and staffing[87](index=87&type=chunk) - The decrease in G&A expenses for the six months ended June 30, 2025, was primarily due to a **$1.2 million** reduction in professional services, partially offset by a **$0.3 million** increase in staffing costs[89](index=89&type=chunk) [Liquidity, Capital Resources and Plan of Operations](index=20&type=section&id=Liquidity%2C%20Capital%20Resources%20and%20Plan%20of%20Operations) The company had **$17.8 million** in cash as of June 30, 2025, and believes it has sufficient liquidity for the next 12 months - The company's cash balance was **$17.8 million** as of June 30, 2025, which management believes is sufficient to fund operations for at least the next 12 months[92](index=92&type=chunk)[94](index=94&type=chunk) - During the six months ended June 30, 2025, the company sold **9,719,173 shares** of common stock through its at-the-market (ATM) offering for net proceeds of **$9.7 million**. The ATM offering was terminated on March 31, 2025[94](index=94&type=chunk) [Cash Flows](index=21&type=section&id=Cash%20Flows) Net cash used in operating activities was **$8.2 million** for H1 2025, with **$8.6 million** provided by financing activities | ($ in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(8,167) | $(8,703) | | Net cash provided by financing activities | $8,578 | $27,689 | | Effect of foreign exchange rates on cash | $(2,143) | $81 | | Net increase (decrease) in cash | $(1,732) | $19,067 | [Quantitative and Qualitative Disclosures About Market Risk](index=22&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, Allarity Therapeutics is exempt from providing quantitative and qualitative disclosures about market risk - As a smaller reporting company, Allarity Therapeutics is exempt from providing quantitative and qualitative disclosures about market risk[107](index=107&type=chunk) [Controls and Procedures](index=22&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were ineffective due to a material weakness in internal control over financial reporting - Management identified a material weakness in internal control over financial reporting as of June 30, 2025[108](index=108&type=chunk) - The material weakness is related to the accounting of the share repurchase plan that was initiated in the quarter ended June 30, 2025[109](index=109&type=chunk) - To remediate the weakness, management plans to update internal controls, implement new policies and procedures, and enhance review processes for contractual agreements[109](index=109&type=chunk)[114](index=114&type=chunk) PART II—OTHER INFORMATION [Legal Proceedings](index=24&type=section&id=Item%201.%20Legal%20Proceedings) Information on material legal proceedings, including the SEC investigation settlement, is incorporated by reference from Note 9 - Information regarding material legal proceedings is incorporated by reference from Note 9, which discusses the SEC investigation and settlement[116](index=116&type=chunk)[67](index=67&type=chunk) [Risk Factors](index=24&type=section&id=Item%201A.%20Risk%20Factors) The company updated its risk factors to include a material weakness in internal control over financial reporting, potentially impacting financial report reliability - A new risk factor was added to reflect the identification of material weaknesses in the company's internal control over financial reporting as of June 30, 2025[117](index=117&type=chunk) - The material weakness could limit the company's ability to prevent or detect a material misstatement in its financial statements, potentially leading to non-compliance with SEC filing requirements and a decline in stock price[118](index=118&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=25&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section details the company's share repurchases, including the repurchase of **2,455,702 shares** during Q2 2025 | Period | Total Number of Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | April, 2025 | 1,857,024 | $1.07 | | May, 2025 | 99,242 | $1.12 | | June, 2025 | 499,436 | $0.94 | | **Total Q2 2025** | **2,455,702** | **N/A** | - The board of directors approved a share repurchase program on March 3, 2025, authorizing up to **$5 million** in purchases. As of the end of June 2025, **$2,434,489** remained available for future repurchases under the plan[122](index=122&type=chunk) [Other Information](index=25&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted or terminated Rule 10b5-1 trading arrangements during Q2 2025 - No directors or officers adopted or terminated a Rule 10b5-1 trading plan during the second quarter of 2025[125](index=125&type=chunk) [Exhibits](index=26&type=section&id=Item%206.%20Exhibits) This section provides an index of exhibits filed with the Quarterly Report on Form 10-Q, including required certifications

Core Insights - Allarity Therapeutics has successfully initiated enrollment in an advanced Phase 2 clinical trial for ovarian cancer, focusing on recurrent, platinum-resistant or platinum-ineligible patients [1][6] - The company has expanded its global intellectual property (IP) protection by securing an Australian patent for the stenoparib DRP companion diagnostic, which includes 40 claims [5] - A new service contract has been secured with a European biotech for Allarity Medical Laboratory, enhancing revenue opportunities [1][10] Clinical and Drug Development Progress - The Phase 2 clinical trial for stenoparib is progressing well, with initial patient dosing reflecting strong engagement from investigators [6] - A partnership has been initiated with the Indiana Biosciences Research Institute to conduct advanced studies on the anti-cancer effects of stenoparib, potentially expanding its therapeutic applications [6] - The company is also advancing a Veterans Administration-funded combination trial of stenoparib and temozolomide in small cell lung cancer, with patient recruitment expected to begin in the second half of 2025 [10] Financial Performance - As of June 30, 2025, Allarity reported cash and cash equivalents of $17.8 million, down from $19.5 million at the end of 2024 [16] - The company reduced its accounts payable and accrued expenses by $2 million during the quarter, indicating improved financial management [2][10] - Research and Development (R&D) expenses for the second quarter of 2025 were $2.3 million, compared to $1.06 million in the same quarter of 2024, reflecting ongoing clinical advancement activities [10][18] Corporate and Strategic Developments - Allarity has made significant progress in strengthening its leadership team, with new appointments to the Board of Directors and executive positions [10] - The company has launched a refined monotherapy trial protocol for stenoparib, which is now steadily enrolling patients [3][10] - Allarity's DRP platform has been expanded to include a new DRP for the antibody therapy daratumumab, showcasing its broad applicability across various cancer types [10]

Core Insights - Allarity Therapeutics has signed a new commercial agreement with a non-disclosed EU-based biotechnology company, granting a non-exclusive global license to selected proprietary Drug Response Predictor (DRP) algorithms in breast cancer, along with laboratory services from Allarity's Medical Laboratory in Denmark [1][2] Group 1: Agreement Details - The agreement includes advanced transcriptome analysis services to support the partner's precision oncology solutions in breast cancer and secures purchase commitments for Allarity's laboratory services over the next year [2] - The financial impact of this agreement on Allarity's outlook is not expected to be significant [2] Group 2: Technology and Expertise - The agreement validates the broad applicability of Allarity's DRP technology, which is based on decades of research and development, aimed at improving patient selection and treatment outcomes [3] - Allarity's DRP platform utilizes advanced gene expression profiling to predict individual tumor responses to specific therapies, covering over 100 drugs, including investigational compounds and approved drugs [3][5] Group 3: Product Information - Stenoparib, developed by Allarity, is a dual-targeted inhibitor of PARP1/2 and tankyrase 1/2, showing potential as a therapeutic for various cancers, including ovarian cancer [4] - The company holds exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. [4][6] Group 4: Company Overview - Allarity Therapeutics is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments, particularly through the use of its DRP technology for selecting patients who may benefit most from stenoparib [6]

Core Insights - Allarity Therapeutics has appointed Jeff Ervin as the new Chief Financial Officer, succeeding Alexander Epshinsky, who will assist during the transition period [1][3] Group 1: Leadership Appointment - Jeff Ervin brings nearly two decades of executive leadership experience in healthcare and biotech, previously serving as Co-CFO at DayDayCook and CEO at IMAC Holdings [2] - Ervin holds an MBA in Finance and Strategy from Vanderbilt University and a BS in Finance from Miami University, with additional education in corporate strategy from Stanford University [3] Group 2: Company Focus and Technology - Allarity is focused on developing stenoparib, a dual PARP and WNT pathway inhibitor, as a personalized cancer treatment using its proprietary Drug Response Predictor (DRP) technology [1][4] - Stenoparib targets PARP1/2 and tankyrase 1/2, showing potential for treating various cancers, including ovarian cancer, and has exclusive global rights for its development and commercialization [4][6] Group 3: Drug Response Predictor (DRP) - The DRP technology selects patients likely to benefit from specific drugs based on gene expression signatures, enhancing therapeutic benefit rates [5] - The DRP platform has demonstrated statistically significant predictions of clinical outcomes across numerous studies, making it applicable to all cancer types and patented for various anti-cancer drugs [5]

Core Viewpoint - Allarity Therapeutics has received formal acceptance of its patent application for the Drug Response Predictor (DRP) companion diagnostic specific to stenoparib from IP Australia, marking a significant step in its global strategy for intellectual property protection and commercialization of its proprietary technology [1][2][3]. Company Overview - Allarity Therapeutics, Inc. is a Phase 2 clinical-stage pharmaceutical company focused on developing stenoparib, a dual PARP and WNT pathway inhibitor, as a personalized cancer treatment using its proprietary DRP technology [1][6]. - The company is headquartered in the U.S. and has a research facility in Denmark, aiming to address significant unmet medical needs in cancer treatment [6]. Patent and Intellectual Property - The accepted patent covers 40 claims and is a crucial part of Allarity's strategy to protect its DRP platform internationally, with the patent expected to be granted within 20 working days if unopposed [2][3]. - Allarity has previously secured a European patent for the stenoparib DRP and holds 18 granted patents for drug-specific DRPs, including eight in the U.S. [3]. Drug and Technology Details - Stenoparib is an orally available small-molecule inhibitor targeting PARP1/2 and tankyrase 1/2, with potential applications in various cancer types, particularly ovarian cancer [4]. - The DRP technology is designed to select patients likely to benefit from specific drugs based on gene expression signatures, enhancing therapeutic benefit rates [5]. Future Prospects - The acceptance of the Australian patent is seen as a vital achievement in securing international IP protection while advancing stenoparib through Phase 2 trials towards U.S. regulatory approval [3].